Skip to main content
Figure 5 | Molecular Neurodegeneration

Figure 5

From: The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Figure 5

Everolimus decreases LAMP1 expression in muscle, but not brain. A-B. Lysosome-associated membrane protein 1 (LAMP1) is increased in mouse HD striatal and cortical neurons (green) as measured by quantitative immunofluorescence. Ethidium dimer DNA/RNA counter stain (red). n = 5. C-D. There is no effect of everolimus on LAMP1 levels in striatum or cortex as measured by Western blot analysis. E-F. LAMP1 is increased in quadriceps femoris muscle; levels are significantly reduced by high-dose everolimus. Shown are means and standard errors. X-axes show genotype-dose combinations (C, D and F). TG = transgenic, WT = wild-type. n = 8-10. p-values: * = p < 0.05, ** = p < 0.01.

Back to article page